Oleksandra Lupak, MD in Charleston, SC ...

Dr. Oleksandra Lupak

Claim this profile

Ralph H Johnson VA Medical Center

Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
12 reported clinical trials
24 drugs studied

Area of expertise

1Non-Small Cell Lung Cancer
Oleksandra Lupak has run 4 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
MET positive
EGFR positive
2Lung Cancer
Oleksandra Lupak has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
EGFR positive
ALK positive

Affiliated Hospitals

Image of trial facility.
Ralph H. Johnson VA Medical Center
Image of trial facility.
Medical University Of South Carolina

Clinical Trials Oleksandra Lupak is currently running

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria

More about Oleksandra Lupak

Clinical Trial Related3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Oleksandra Lupak has experience with
  • Lenalidomide
  • Nivolumab
  • Oxaliplatin
  • Daratumumab/rHuPH20
  • Screening Platform
  • Dexamethasone

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Oleksandra Lupak specialize in?
Is Oleksandra Lupak currently recruiting for clinical trials?
Are there any treatments that Oleksandra Lupak has studied deeply?
What is the best way to schedule an appointment with Oleksandra Lupak?
What is the office address of Oleksandra Lupak?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security